Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04934085
Other study ID # COVID-19
Secondary ID
Status Completed
Phase
First received
Last updated
Start date June 30, 2021
Est. completion date August 30, 2021

Study information

Verified date September 2021
Source University of Rzeszow
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The research will make it possible to assess patients who recovered from COVID-19 for the incidence of neurological problems (impaired balance, gait, coordination, concentration and attention), and changes in the quality of life, physical activity, social contacts and education.


Description:

The intended size of group - 100 subjects (50 subjects - study group, 50 subjects - control group). The above population was determined based on sample size calculator, with the following parameters: fraction size of 0.9, Confidence Interval of 95%, maximum error of 9%. The proper study will be preceded with a pilot study involving a smaller group of subjects (in order to standardise the surveys, and minimise the relationship between the results of the survey and side-effect factors). After inclusion and exclusion criteria are considered, the subjects will be allocated into two groups: - study group (subjects who had tested positive and recovered from COVID-19) - control group (healthy subjects who did not have COVID-19). The controls will be matched to the study group for gender and age. The examination will be performed once, at the premises of the University of Rzeszów. The participants' condition will be assessed using the following measures: - static and dynamic balance and risk of falls (force plate and computerised posturography, clinical tests) - activity in the cerebral cortex of the frontal lobe during focused performance of a task (Hemoencephalography HEG-System) - concentration and attention, memory and cognitive functions (Bourdon-Wiersma test and Auditory-Verbal Learning Test) - gait velocity and efficiency (10-meter walk test and 6-minute walk test) - physical activity (International Physical Activity Questionnaire IPAQ), as well as education, mood, and social contacts (specially designed questionnaire) - quality of life (SF-36 questionnaire)


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date August 30, 2021
Est. primary completion date July 30, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 19 Years to 26 Years
Eligibility Inclusion Criteria: - Informed consent to participate in the study. - Experienced infection with SARS-COV-2. - Age 19 - 26 years - No injuries to lower limbs in the period of 12 months preceding the date of enrolment into the study - No orthopaedic disorders affecting the lower limbs (including decreased length of the lower limbs) - No diagnosed neurological diseases or disorders (including labyrinth dysfunction) - No diagnosed impairment of concentration and attention Exclusion Criteria: - Lack of informed consent to participate in the study - No experience of infection with SARS-COV-2 - Age outside the range of 19 and 27 years - Confirmed injuries to lower limbs in the period of 12 months preceding the date of enrolment into the study - Confirmed neurological diseases or disorders, such as impaired balance, concentration and attention.

Study Design


Locations

Country Name City State
Poland University of Rzeszów Rzeszów Podkarpackie

Sponsors (1)

Lead Sponsor Collaborator
University of Rzeszow

Country where clinical trial is conducted

Poland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Static balance measurements to be performed with a force plate. Centre of Foot Pressure (COP) movements will be assessed in the frontal and sagittal plane (95% confidence ellipse area (COP-area mm2), medium antero-posterior and lateral sway COP (mm), COP average velocity (mm/sec). Stabilographic measurements, each continued for 60 seconds, will be carried out during the following trials: standing on stable ground with eyes open and with eyes closed; standing on unstable ground with eyes open and with eyes closed. up to 1 month
Primary Dynamic balance measurements to be performed using computerised dynamic posturography. The assessment will be performed using Smart EquiTest System from Neurocom. The assessment with take into account delay in response to a destabilising stimulus of mild, moderate and high strength (motor control test - one of the available standard research protocols). The assessment will take into account: Latency - time lapse (in milliseconds) between the onset of support surface translation and the participant's active force response, measured for each limb independently; and Amplitude scaling (or Relative response strength) - strength of the participant's active force response to arrest the angular momentum imparted to the body during the backwards and forwards translations. The response strength will be measured for each leg independently in units of angular momentum (degrees/second) and normalized to body height and weight. up to 1 month
Primary Activity in the cerebral cortex of the frontal lobe measurements to be performed with Hemoencephalography HEG - a system for imaging of cerebral blood oxygenation as well as brain activity. During the examination HEG headset will be placed on the subject's forehead, and any external light stimuli, which could affect the results, will be eliminated. The subject will be required to fully focus on the image displayed on a screen. The examination will comprise a 10-minute session, preceded with one minute test trial during which the indicators will be normalised and the subjects will be prepared for the task. The assessment will take into account HEG ratio mean, max and min. The HEG ratio is: red light (nm) / infrared light (nm) up to 1 month
Secondary Concentration and attention measurements to be performed with Bourdon-Wiersma test. During the trial the subject is shown a sheet with a sequence of various letters and digits and he/she is asked to cancel specific letters, e.g., e and r in three minutes. The score reflects the total number of accurately cancelled letters, and a total number of letters omitted or cancelled inaccurately. up to 1 month
Secondary Memory and cognitive functions measurements to be performed with Auditory-Verbal Learning Test (AVLT). During the trial the subject is asked to repeat a list of 15 words. up to 1 month
Secondary Walking speed measurements to be performed with a 10-meter walk test. During the trials assessing gait velocity (m/s) over a distance of 10 metres, the subjects walk at a self-selected speed. up to 1 month
Secondary Walking distance measurements to be performed with a 6-minute walk test. During the trial, the subjects walk at a self-selected speed for 6 minutes. up to 1 month
Secondary Self-reliant mobility measurements to be performed with the Timed Up and Go Test. During the trial, the subjects are instructed to get up from a chair with a standard-height backrest and to walk 3 metres, turn round at a specified location, return to the chair and resume the sitting position unassisted up to 1 month
Secondary Balance measurements to be performed with Tandem Tests and with a 15-second step test. During Tandem test trials subjects are asked to assume a "tip-top" balance position - the heel of a dominant foot touches the toe of the other with each step. The tasks are used to assess coordination, static and dynamic balance in order to determine the risk of falls. During the 15-second step test, the subject should make as many steps as possible and descend with the entire foot from a 7.5 cm high bench. up to 1 month
Secondary Balance and lower limbs muscle strength Measurements to be performed with a sit-to-stand test. During the trial, the subject should perform as many repetitions of standing up and sitting down from a 43.2 cm tall chair in 30 seconds. up to 1 month
Secondary Health-related quality of life Measurements to be performed with 20-Item Short Form Survey (SF-20). This questionnaire is a short multi-dimensional instrument that measures six aspects of health status: physical functioning (6 items), role functioning (2 items), social functioning (1 item), mental health (5 items), general health perceptions (5 items), and pain (1 item). up to 1 month
Secondary Physical activity level Measurements to be performed with International Physical Activity Questionnaire Short Form (IPAQ-SF). The short form records the "last 7 days recall" activity of four intensity levels: vigorous-intensity activity, moderate-intensity activity, walking, and sitting. Single examination up to 1 month
Secondary education, mood, physical activity and social contacts measurements to be performed with a specially designed questionnaire. The self-authored questionnaire consists of questions assessing the impact of Covid-19 pandemic and the related restrictions on the quality of education, knowledge acquisition, frequency and form of physical activity performed, as well as mental state, mood, and changes in social contacts. up to 1 month
See also
  Status Clinical Trial Phase
Completed NCT05047692 - Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers Phase 1
Recruiting NCT04395768 - International ALLIANCE Study of Therapies to Prevent Progression of COVID-19 Phase 2
Completed NCT04508777 - COVID SAFE: COVID-19 Screening Assessment for Exposure
Completed NCT04506268 - COVID-19 SAFE Enrollment N/A
Terminated NCT04555096 - A Trial of GC4419 in Patients With Critical Illness Due to COVID-19 Phase 2
Completed NCT04961541 - Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine Phase 1/Phase 2
Active, not recruiting NCT04546737 - Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients N/A
Completed NCT04494646 - BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19) Phase 2
Completed NCT04532294 - Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants Phase 1
Terminated NCT04542993 - Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy Phase 2
Terminated NCT04581915 - PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19 Phase 2/Phase 3
Not yet recruiting NCT04543006 - Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19 N/A
Not yet recruiting NCT04527211 - Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel Phase 3
Completed NCT04387292 - Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic N/A
Completed NCT04537663 - Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults Phase 4
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Not yet recruiting NCT05038449 - Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19 N/A
Completed NCT04979858 - Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask N/A
Completed NCT04610502 - Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients Phase 2
Active, not recruiting NCT06042855 - ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin) Phase 3